Geron Corporation (GERN) Stock Ticker
GERN right now
Market factors today
Unlock the full GERN picture
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN stock facts
| Ticker symbol | GERN |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $808.3M |
| CEO | Harout Semerjian |
| Employees | 258 |
| Headquarters | Foster City, CA, US |
| IPO date | 1996-07-31 |
| Website | www.geron.com |
What you can see for GERN on Tickr
Live GERN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GERN report.
Rankings
FAQ
What is the ticker symbol for Geron Corporation?
The ticker symbol for Geron Corporation is GERN, listed on the NASDAQ Global Select.
What is GERN?
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid…